{"id":"typhoid-vi-polysaccharide","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved by presenting the Vi polysaccharide antigen to the immune system, which then mounts a specific response against the bacteria. The vaccine does not contain live or attenuated bacteria, making it safe for use in individuals with weakened immune systems.","oneSentence":"Typhoid Vi polysaccharide vaccine induces an immune response against Salmonella Typhi.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:39.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of typhoid fever in individuals traveling to or living in areas where typhoid fever is common"}]},"trialDetails":[{"nctId":"NCT05500482","phase":"PHASE4","title":"Vellore Typhoid Vaccine Impact Trial","status":"COMPLETED","sponsor":"Christian Medical College, Vellore, India","startDate":"2023-05-01","conditions":"Typhoid Fever","enrollment":72400},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT05919472","phase":"NA","title":"Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women","status":"COMPLETED","sponsor":"Nicole Stoffel","startDate":"2023-07-01","conditions":"Iron Deficiency Anemia","enrollment":180},{"nctId":"NCT06817421","phase":"PHASE4","title":"Opportunistic Pneumococcal Immunisation Trial in MALnutrition","status":"NOT_YET_RECRUITING","sponsor":"Nick Fancourt","startDate":"2026-01","conditions":"Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines","enrollment":214},{"nctId":"NCT06630884","phase":"PHASE1","title":"Inflammatory Challenge and Fear","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-28","conditions":"Posttraumatic Stress Disorder (PTSD)","enrollment":288},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT05480800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-09-13","conditions":"Salmonella Infections","enrollment":155},{"nctId":"NCT05745987","phase":"PHASE4","title":"Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT","status":"RECRUITING","sponsor":"McMaster University","startDate":"2024-09-17","conditions":"Monkeypox","enrollment":3000},{"nctId":"NCT06757283","phase":"PHASE3","title":"ZyVac-TCV Bangladesh Study","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-04-01","conditions":"Typhoid Vaccination, Typhoid, Typhoid Fever","enrollment":4000},{"nctId":"NCT05613205","phase":"PHASE1","title":"Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-11-28","conditions":"Typhoid Fever","enrollment":97},{"nctId":"NCT05475379","phase":"PHASE1, PHASE2","title":"Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-07-01","conditions":"Typhoid","enrollment":630},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT02429531","phase":"PHASE4","title":"Polysaccharide Antibody Response Study","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2015-10","conditions":"Specific Polysaccharide Antibody Deficiency","enrollment":200},{"nctId":"NCT03968211","phase":"PHASE1","title":"Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2019-07-01","conditions":"Immune Deficiency","enrollment":37},{"nctId":"NCT04852185","phase":"PHASE4","title":"Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2021-08-24","conditions":"Typhoid Fever","enrollment":23000},{"nctId":"NCT06116669","phase":"NA","title":"Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women","status":"UNKNOWN","sponsor":"Swiss Federal Institute of Technology","startDate":"2023-11-01","conditions":"Iron Deficiency Anemia","enrollment":180},{"nctId":"NCT06027801","phase":"NA","title":"Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2023-09-06","conditions":"Iron Deficiency Anemia","enrollment":150},{"nctId":"NCT05771779","phase":"PHASE3","title":"Co-administration Study of OCV, TCV and MR","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-10-14","conditions":"Typhoid, Cholera, Measles","enrollment":2117},{"nctId":"NCT05346302","phase":"EARLY_PHASE1","title":"Persistent Readiness Through Early Prediction Immunization Study","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2022-02-08","conditions":"Inflammatory Response","enrollment":249},{"nctId":"NCT02715635","phase":"PHASE1","title":"Influence of Dietary Nitrate on Vascular Dysfunction and Inflammation","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2016-04","conditions":"Cardiovascular Diseases","enrollment":78},{"nctId":"NCT02324751","phase":"PHASE2","title":"Vaccines Against Salmonella Typhi","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-09","conditions":"Typhoid Fever, Enteric Fever","enrollment":112},{"nctId":"NCT00875524","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-03","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":180},{"nctId":"NCT04051268","phase":"PHASE3","title":"Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2020-03-02","conditions":"Safety Issues, Immunogenicity","enrollment":3071},{"nctId":"NCT03889158","phase":"PHASE4","title":"Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2019-03-25","conditions":"Aging, Inflammation","enrollment":35},{"nctId":"NCT03554213","phase":"","title":"Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-07-02","conditions":"Enteric Fever, Typhoid Fever, Salmonella Typhi Infection","enrollment":17292},{"nctId":"NCT04204096","phase":"PHASE3","title":"Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2020-02-04","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT03527355","phase":"PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2018-04-18","conditions":"Typhoid","enrollment":285},{"nctId":"NCT03048929","phase":"EARLY_PHASE1","title":"Inflammation and Threat Sensitivity in PTSD","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-04-01","conditions":"Posttraumatic Stress Disorder","enrollment":30},{"nctId":"NCT02645032","phase":"PHASE1","title":"Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2016-05-19","conditions":"Typhoid","enrollment":144},{"nctId":"NCT03933098","phase":"PHASE3","title":"Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2019-11-15","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT03460405","phase":"PHASE2","title":"Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2018-07-16","conditions":"Safety Issues, Immunogenicity","enrollment":600},{"nctId":"NCT03956524","phase":"PHASE1","title":"Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2019-03-16","conditions":"Typhoid Fever","enrollment":75},{"nctId":"NCT03294564","phase":"EARLY_PHASE1","title":"Cognitive, Emotional, and Neural Responses to Acute Inflammation","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-01-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT02628054","phase":"NA","title":"Investigating the Effects of Typhoid Vaccine on Sleep in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-02","conditions":"Typhoid Vaccine on Sleep","enrollment":16},{"nctId":"NCT03109600","phase":"PHASE1","title":"Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2017-04-18","conditions":"Safety Issues","enrollment":100},{"nctId":"NCT02286544","phase":"PHASE1","title":"Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2014-10","conditions":"Myocardial Infarction, Inflammation, Acute Coronary Syndrome (ACS)","enrollment":36},{"nctId":"NCT01582321","phase":"EARLY_PHASE1","title":"Investigation of the Influence of Gender on Cardiovascular Function","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2012-03","conditions":"Cardiovascular Function","enrollment":56},{"nctId":"NCT00197249","phase":"PHASE3","title":"Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-05","conditions":"Hepatitis A","enrollment":1034},{"nctId":"NCT02175420","phase":"NA","title":"Role of BCG as Booster Vaccination","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2012-07","conditions":"BCG Vaccination","enrollment":30},{"nctId":"NCT01608815","phase":"PHASE3","title":"Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-05","conditions":"Salmonella Infections, Typhoid Fever, Bacterial Infections","enrollment":200},{"nctId":"NCT00326443","phase":"PHASE1","title":"CVD 909 Vi Prime Boost Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"Typhoid Fever","enrollment":21},{"nctId":"NCT01533285","phase":"EARLY_PHASE1","title":"Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2012-05","conditions":"Major Depressive Disorder","enrollment":40},{"nctId":"NCT01438996","phase":"PHASE2","title":"Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-10","conditions":"Typhoid Fever","enrollment":51},{"nctId":"NCT01466387","phase":"PHASE3","title":"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-11","conditions":"Meningococcal Disease, Meningococcal Meningitis, Typhoid","enrollment":552},{"nctId":"NCT01193907","phase":"PHASE2","title":"Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Typhoid Fever","enrollment":88},{"nctId":"NCT01123941","phase":"PHASE1","title":"Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-05","conditions":"Typhoid Fever","enrollment":50},{"nctId":"NCT00342628","phase":"PHASE2","title":"Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-07","conditions":"Typhoid Fever","enrollment":301},{"nctId":"NCT00125047","phase":"PHASE4","title":"Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2001-10","conditions":"Typhoid, Paratyphoid Fever","enrollment":27231},{"nctId":"NCT00125008","phase":"PHASE4","title":"Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2003-05","conditions":"Typhoid, Paratyphoid Fever","enrollment":37673},{"nctId":"NCT00131820","phase":"PHASE4","title":"Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2001-12","conditions":"Typhoid, Paratyphoid Fever","enrollment":100742},{"nctId":"NCT00131833","phase":"PHASE4","title":"Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2001-10","conditions":"Typhoid, Paratyphoid Fever","enrollment":96468}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Typhim Vi"],"phase":"phase_3","status":"active","brandName":"Typhoid Vi polysaccharide","genericName":"Typhoid Vi polysaccharide","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"Typhoid Vi polysaccharide is a vaccine component used to prevent infections caused by Salmonella Typhi, a bacterium that can lead to conditions such as Typhoid and Paratyphoid Fever. It is a vaccine component, as indicated by its listing in ChEMBL, and has been studied in various clinical trials, including those for Typhoid Fever and Salmonella Infections, as listed on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}